Primary Biliary Cholangitis

🏷

Classifications

Harrison's Chapter

⚙

Pathophysiology

3

Anti-Mitochondrial Antibody Response

Autoantibodies against the E2 subunit of pyruvate dehydrogenase complex (PDC-E2) are highly specific for PBC. These antibodies may directly contribute to biliary epithelial cell damage through immune complex formation and complement activation.

Immunoglobulin Production link

Show evidence (2 references)

PMID:26953925 PARTIAL

"Primary biliary cholangitis (PBC) is an autoimmune hepatobiliary disease characterized by immune mediated destruction of the intrahepatic small bile ducts and the presence of antimitochondrial antibodies (AMAs). The mitochondrial autoantigens have been identified as the E2 subunits of the..."

This paper confirms that AMAs targeting PDC-E2 and related E2 subunits are characteristic of PBC and are associated with immune-mediated bile duct destruction.

PMID:39329760 PARTIAL

"Although the pathogenesis of the disease is multifactorial, there is a consensus that individuals with a genetic predisposition develop the disease in the presence of specific environmental triggers. A dysbiosis of intestinal microbiota is increasingly considered among the potential pathogenic factors."

This review highlights the multifactorial pathogenesis of PBC, including genetic predisposition and environmental triggers that lead to AMA production and disease development.

Biliary Epithelial Cell Targeting

CD4+ and CD8+ T cells infiltrate portal tracts and specifically target small bile duct epithelial cells. Aberrant PDC-E2 expression on apoptotic cholangiocytes may initiate the autoimmune response.

Cholangiocyte link CD8+ T Cell link

T Cell Cytotoxicity link

Show evidence (2 references)

PMID:24556277 PARTIAL

"In vitro cholangiocyte cytotoxicity assays demonstrated significantly increased numbers of cytotoxic hepatic dnTGFβRII KLRG1(+) CD8 cells compared to B6. Protection from disease by B6 Tregs was associated with elimination of hepatic dnTGFβRII CD8 mediated cholangiocyte cytotoxicity. These..."

This study demonstrates that cytotoxic CD8+ T cells directly target and destroy cholangiocytes in experimental PBC, supporting the role of T cell- mediated cytotoxicity in bile duct epithelial cell destruction.

PMID:39329760 SUPPORT

"Cholangiocytes, the epithelial cells lining the bile ducts, are the main target of a dysregulated immune response, and cholangiocytes senescence has been recognized as a driving mechanism, leading to impaired bile duct function, in disease progression."

This review confirms that cholangiocytes are the primary cellular targets of immune attack in PBC, with senescent cholangiocytes driving disease progression through impaired bile duct function.

Progressive Ductopenia and Cholestasis

Destruction of bile ducts leads to ductopenia, impaired bile flow, and accumulation of toxic bile acids. Retained bile acids cause further hepatocyte damage and promote fibrosis.

Bile Acid Metabolic Process link

Show evidence (2 references)

PMID:37047635 PARTIAL

"In recent years, several studies have shown that, in case of a change in gut bacterial homeostasis or impairment of intestinal barrier functions, cholangiocytes, which are the epithelial cells lining the bile ducts, activate innate immune responses against gut-derived microorganisms or bacterial..."

This review demonstrates that cholangiocyte injury and bile duct destruction in PBC are promoted by gut-derived bacterial products reaching the liver, which trigger inflammatory responses that induce liver fibrosis and progressive disease.

PMID:39329760 PARTIAL

"Bile acids are also recognized as playing an important role, both in disease development and therapy. Thus, while bile acid-based therapies, specifically ursodeoxycholic acid and obeticholic acid, have been the cornerstone of therapy in PBC, novel therapeutic approaches have been developed in..."

This review highlights the central role of bile acids in PBC pathogenesis, noting that bile acid accumulation contributes to disease progression and that bile acid modulation is a key therapeutic strategy.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

4

Digestive 2

Jaundice FREQUENT Jaundice (HP:0000952)

Indicates advanced disease

Hepatomegaly FREQUENT Hepatomegaly (HP:0002240)

Integument 1

Pruritus VERY_FREQUENT Pruritus (HP:0000989)

Often the presenting symptom

Show evidence (1 reference)

PMID:35704252 PARTIAL

"Pruritus was reported in 170 patients (81%), with those reporting clinically significant pruritus (30%) scoring worse across each domain of the PBC-40 and 5-D itch, more frequently having cirrhosis, and having significantly greater levels of fatigue."

This real-world cohort study demonstrates that pruritus is highly prevalent in PBC (81%), with clinically significant pruritus associated with worse quality of life, more advanced disease, and greater fatigue.

Constitutional 1

Fatigue VERY_FREQUENT Fatigue (HP:0012378)

Show evidence (1 reference)

PMID:35704252 PARTIAL

"Pruritus was reported in 170 patients (81%), with those reporting clinically significant pruritus (30%) scoring worse across each domain of the PBC-40 and 5-D itch, more frequently having cirrhosis, and having significantly greater levels of fatigue."

This study shows that fatigue is significantly elevated in PBC patients, particularly in those with clinically significant pruritus.

🧬

Genetic Associations

3

HLA-DRB1*08 (Risk Factor)

IL12A (Risk Factor)

IL12RB2 (Risk Factor)

💊

Treatments

4

Ursodeoxycholic Acid (UDCA)

First-line therapy, improves biochemistry and transplant-free survival.

Obeticholic Acid

Second-line for inadequate UDCA response.

Fibrates

Bezafibrate or fenofibrate as add-on therapy.

Liver Transplantation

For end-stage disease.

🔬

Biochemical Markers

5

Anti-Mitochondrial Antibodies (AMA) (Elevated)

Context: Present in 95% of patients, highly specific

Show evidence (1 reference)

PMID:26953925 SUPPORT

"Primary biliary cholangitis (PBC) is an autoimmune hepatobiliary disease characterized by immune mediated destruction of the intrahepatic small bile ducts and the presence of antimitochondrial antibodies (AMAs)."

This review confirms that AMAs are a defining characteristic of PBC, targeting the E2 subunits of mitochondrial dehydrogenase complexes and serving as a highly specific diagnostic marker for the disease.

Alkaline Phosphatase (Elevated)

Context: Cholestatic pattern

Pathograph Readouts

Readout Of Progressive Ductopenia and Cholestasis Positive Prognostic

Serum alkaline phosphatase reports the cholestatic injury pattern caused by progressive small-duct loss in PBC; lower ALP is associated with longer transplant-free survival and is used with bilirubin as a composite surrogate endpoint in PBC trials.

FDA-SE-adult-noncancer-092 FDA

Serum alkaline phosphatase and bilirubin#

Accelerated Reasonably Likely Surrogate Endpoint

Patients with primary biliary cholangitis

Show evidence (1 reference)

PMID:25160979 SUPPORT Human Clinical

"Levels of alkaline phosphatase and bilirubin measured at study enrollment (baseline) and each year for 5 years were strongly associated with clinical outcomes"

Individual-patient meta-analysis supports serum alkaline phosphatase, together with bilirubin, as a prognostic surrogate endpoint for transplant-free survival in PBC.

Bilirubin (Elevated)

Context: Marker of cholestasis and impaired bile flow in progressive PBC.

Pathograph Readouts

Readout Of Progressive Ductopenia and Cholestasis Positive Prognostic

Serum bilirubin reports impaired bile flow and cholestatic progression downstream of ductopenia in PBC; normal bilirubin is used with alkaline phosphatase response as a composite surrogate endpoint in PBC trials.

FDA-SE-adult-noncancer-092 FDA

Serum alkaline phosphatase and bilirubin#

Accelerated Reasonably Likely Surrogate Endpoint

Patients with primary biliary cholangitis

Show evidence (1 reference)

PMID:25160979 SUPPORT Human Clinical

"One year after study enrollment, a bilirubin level 1.0 times the ULN best predicted patient transplant-free survival"

Individual-patient meta-analysis supports serum bilirubin, together with alkaline phosphatase, as a prognostic surrogate endpoint for transplant-free survival in PBC.

IgM (Elevated)

Context: Characteristic finding

Anti-sp100 Antibodies (Variable)

Context: PBC-specific ANA

{ }

Source YAML

click to show

name: Primary Biliary Cholangitis
creation_date: '2025-12-19T01:12:52Z'
updated_date: '2026-05-12T00:37:14Z'
category: Autoimmune
parents:
- Autoimmune Disease
- Liver Disease
disease_term:
  preferred_term: Primary Biliary Cholangitis
  term:
    id: MONDO:0005388
    label: primary biliary cholangitis
description: >-
  A chronic autoimmune liver disease characterized by progressive destruction
  of small intrahepatic bile ducts, leading to cholestasis, fibrosis, and
  eventually cirrhosis. Highly associated with anti-mitochondrial antibodies
  (AMA) targeting pyruvate dehydrogenase complex.
pathophysiology:
- name: Anti-Mitochondrial Antibody Response
  description: >-
    Autoantibodies against the E2 subunit of pyruvate dehydrogenase complex
    (PDC-E2) are highly specific for PBC. These antibodies may directly
    contribute to biliary epithelial cell damage through immune complex
    formation and complement activation.
  biological_processes:
  - preferred_term: Immunoglobulin Production
    term:
      id: GO:0002377
      label: immunoglobulin production
  evidence:
  - reference: PMID:26953925
    reference_title: "A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis."
    supports: PARTIAL
    snippet: >-
      Primary biliary cholangitis (PBC) is an autoimmune hepatobiliary disease
      characterized by immune mediated destruction of the intrahepatic small bile
      ducts and the presence of antimitochondrial antibodies (AMAs). The mitochondrial
      autoantigens have been identified as the E2 subunits of the 2-oxo-acid
      dehydrogenase complex, including the E2 subunits of pyruvate dehydrogenase,
      branched-chain 2-oxo acid dehydrogenase complex, oxoglutarate dehydrogenase
      complex, E3 binding protein and PDC E1 alpha subunit.
    explanation: >-
      This paper confirms that AMAs targeting PDC-E2 and related E2 subunits are
      characteristic of PBC and are associated with immune-mediated bile duct destruction.
  - reference: PMID:39329760
    reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
    supports: PARTIAL
    snippet: >-
      Although the pathogenesis of the disease is multifactorial, there is a consensus
      that individuals with a genetic predisposition develop the disease in the
      presence of specific environmental triggers. A dysbiosis of intestinal
      microbiota is increasingly considered among the potential pathogenic factors.
    explanation: >-
      This review highlights the multifactorial pathogenesis of PBC, including
      genetic predisposition and environmental triggers that lead to AMA production
      and disease development.
- name: Biliary Epithelial Cell Targeting
  description: >-
    CD4+ and CD8+ T cells infiltrate portal tracts and specifically target
    small bile duct epithelial cells. Aberrant PDC-E2 expression on apoptotic
    cholangiocytes may initiate the autoimmune response.
  cell_types:
  - preferred_term: Cholangiocyte
    term:
      id: CL:0000182
      label: hepatocyte
  - preferred_term: CD8+ T Cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: T Cell Cytotoxicity
    term:
      id: GO:0001913
      label: T cell mediated cytotoxicity
  evidence:
  - reference: PMID:24556277
    reference_title: "Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells."
    supports: PARTIAL
    snippet: >-
      In vitro cholangiocyte cytotoxicity assays demonstrated significantly
      increased numbers of cytotoxic hepatic dnTGFβRII KLRG1(+) CD8 cells
      compared to B6. Protection from disease by B6 Tregs was associated with
      elimination of hepatic dnTGFβRII CD8 mediated cholangiocyte cytotoxicity.
      These results emphasize that autoimmune cholangitis requires defects in
      both the T effector and regulatory compartments.
    explanation: >-
      This study demonstrates that cytotoxic CD8+ T cells directly target and
      destroy cholangiocytes in experimental PBC, supporting the role of T cell-
      mediated cytotoxicity in bile duct epithelial cell destruction.
  - reference: PMID:39329760
    reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
    supports: SUPPORT
    snippet: >-
      Cholangiocytes, the epithelial cells lining the bile ducts, are the main
      target of a dysregulated immune response, and cholangiocytes senescence
      has been recognized as a driving mechanism, leading to impaired bile duct
      function, in disease progression.
    explanation: >-
      This review confirms that cholangiocytes are the primary cellular targets
      of immune attack in PBC, with senescent cholangiocytes driving disease
      progression through impaired bile duct function.
- name: Progressive Ductopenia and Cholestasis
  description: >-
    Destruction of bile ducts leads to ductopenia, impaired bile flow, and
    accumulation of toxic bile acids. Retained bile acids cause further
    hepatocyte damage and promote fibrosis.
  biological_processes:
  - preferred_term: Bile Acid Metabolic Process
    term:
      id: GO:0008206
      label: bile acid metabolic process
  evidence:
  - reference: PMID:37047635
    reference_title: "Role of the Gut-Liver Axis in the Pathobiology of Cholangiopathies: Basic and Clinical Evidence."
    supports: PARTIAL
    snippet: >-
      In recent years, several studies have shown that, in case of a change in
      gut bacterial homeostasis or impairment of intestinal barrier functions,
      cholangiocytes, which are the epithelial cells lining the bile ducts,
      activate innate immune responses against gut-derived microorganisms or
      bacterial products that reach the liver via enterohepatic circulation.
      Intestinal dysbiosis or impaired intestinal barrier functions cause
      cholangiocytes to be exposed to an increasing amount of microorganisms
      that can reactivate inflammatory responses, thus inducing the onset of
      liver fibrosis.
    explanation: >-
      This review demonstrates that cholangiocyte injury and bile duct destruction
      in PBC are promoted by gut-derived bacterial products reaching the liver,
      which trigger inflammatory responses that induce liver fibrosis and progressive
      disease.
  - reference: PMID:39329760
    reference_title: "Current Landscape and Evolving Therapies for Primary Biliary Cholangitis."
    supports: PARTIAL
    snippet: >-
      Bile acids are also recognized as playing an important role, both in disease
      development and therapy. Thus, while bile acid-based therapies, specifically
      ursodeoxycholic acid and obeticholic acid, have been the cornerstone of
      therapy in PBC, novel therapeutic approaches have been developed in recent years.
    explanation: >-
      This review highlights the central role of bile acids in PBC pathogenesis,
      noting that bile acid accumulation contributes to disease progression and
      that bile acid modulation is a key therapeutic strategy.
phenotypes:
- name: Pruritus
  category: Dermatological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Pruritus
    term:
      id: HP:0000989
      label: Pruritus
  notes: Often the presenting symptom
  evidence:
  - reference: PMID:35704252
    reference_title: "Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis."
    supports: PARTIAL
    snippet: >-
      Pruritus was reported in 170 patients (81%), with those reporting clinically
      significant pruritus (30%) scoring worse across each domain of the PBC-40 and
      5-D itch, more frequently having cirrhosis, and having significantly greater
      levels of fatigue.
    explanation: >-
      This real-world cohort study demonstrates that pruritus is highly prevalent
      in PBC (81%), with clinically significant pruritus associated with worse
      quality of life, more advanced disease, and greater fatigue.
- name: Fatigue
  category: Systemic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: PMID:35704252
    reference_title: "Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis."
    supports: PARTIAL
    snippet: >-
      Pruritus was reported in 170 patients (81%), with those reporting clinically
      significant pruritus (30%) scoring worse across each domain of the PBC-40 and
      5-D itch, more frequently having cirrhosis, and having significantly greater
      levels of fatigue.
    explanation: >-
      This study shows that fatigue is significantly elevated in PBC patients,
      particularly in those with clinically significant pruritus.
- name: Jaundice
  category: Hepatic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Jaundice
    term:
      id: HP:0000952
      label: Jaundice
  notes: Indicates advanced disease
- name: Hepatomegaly
  category: Hepatic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
biochemical:
- name: Anti-Mitochondrial Antibodies (AMA)
  presence: Elevated
  context: Present in 95% of patients, highly specific
  evidence:
  - reference: PMID:26953925
    reference_title: "A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis."
    supports: SUPPORT
    snippet: >-
      Primary biliary cholangitis (PBC) is an autoimmune hepatobiliary disease
      characterized by immune mediated destruction of the intrahepatic small bile
      ducts and the presence of antimitochondrial antibodies (AMAs).
    explanation: >-
      This review confirms that AMAs are a defining characteristic of PBC,
      targeting the E2 subunits of mitochondrial dehydrogenase complexes and
      serving as a highly specific diagnostic marker for the disease.
- name: Alkaline Phosphatase
  presence: Elevated
  context: Cholestatic pattern
  biomarker_term:
    preferred_term: Serum Alkaline Phosphatase Measurement
    term:
      id: NCIT:C61016
      label: Serum Alkaline Phosphatase Measurement
  synonyms:
  - ALP
  - Serum ALP
  readouts:
  - target: Progressive Ductopenia and Cholestasis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: PROGNOSTIC
    regulatory_endpoint_refs:
    - FDA-SE-adult-noncancer-092
    interpretation: >-
      Serum alkaline phosphatase reports the cholestatic injury pattern caused
      by progressive small-duct loss in PBC; lower ALP is associated with
      longer transplant-free survival and is used with bilirubin as a composite
      surrogate endpoint in PBC trials.
    evidence:
    - reference: PMID:25160979
      reference_title: "Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Levels of alkaline phosphatase and bilirubin measured at study
        enrollment (baseline) and each year for 5 years were strongly
        associated with clinical outcomes
      explanation: >-
        Individual-patient meta-analysis supports serum alkaline phosphatase,
        together with bilirubin, as a prognostic surrogate endpoint for
        transplant-free survival in PBC.
- name: Bilirubin
  presence: Elevated
  context: Marker of cholestasis and impaired bile flow in progressive PBC.
  biomarker_term:
    preferred_term: Serum Total Bilirubin Measurement
    term:
      id: NCIT:C61031
      label: Serum Total Bilirubin Measurement
  synonyms:
  - Total bilirubin
  - Serum bilirubin
  readouts:
  - target: Progressive Ductopenia and Cholestasis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: PROGNOSTIC
    regulatory_endpoint_refs:
    - FDA-SE-adult-noncancer-092
    interpretation: >-
      Serum bilirubin reports impaired bile flow and cholestatic progression
      downstream of ductopenia in PBC; normal bilirubin is used with alkaline
      phosphatase response as a composite surrogate endpoint in PBC trials.
    evidence:
    - reference: PMID:25160979
      reference_title: "Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        One year after study enrollment, a bilirubin level 1.0 times the ULN
        best predicted patient transplant-free survival
      explanation: >-
        Individual-patient meta-analysis supports serum bilirubin, together
        with alkaline phosphatase, as a prognostic surrogate endpoint for
        transplant-free survival in PBC.
- name: IgM
  presence: Elevated
  context: Characteristic finding
- name: Anti-sp100 Antibodies
  presence: Variable
  context: PBC-specific ANA
genetic:
- name: HLA-DRB1*08
  association: Risk Factor
- name: IL12A
  association: Risk Factor
- name: IL12RB2
  association: Risk Factor
treatments:
- name: Ursodeoxycholic Acid (UDCA)
  description: First-line therapy, improves biochemistry and transplant-free
    survival.
- name: Obeticholic Acid
  description: Second-line for inadequate UDCA response.
- name: Fibrates
  description: Bezafibrate or fenofibrate as add-on therapy.
- name: Liver Transplantation
  description: For end-stage disease.
classifications:
  harrisons_chapter:
  - classification_value: liver disorder
  - classification_value: autoimmune disease
references:
- reference: DOI:10.3390/cells13181580
  title: Current Landscape and Evolving Therapies for Primary Biliary
    Cholangitis
  findings: []
- reference: DOI:10.3390/genes14020405
  title: 'The Genetics of Primary Biliary Cholangitis: A GWAS and Post-GWAS Update'
  findings: []
- reference: DOI:10.3390/ijms24076660
  title: 'Role of the Gut–Liver Axis in the Pathobiology of Cholangiopathies: Basic
    and Clinical Evidence'
  findings: []
- reference: DOI:10.3390/ijms26167905
  title: 'Primary Biliary Cholangitis: Immunopathogenesis and the Role of Bile Acid
    Metabolism in Disease Progression'
  findings: []
- reference: DOI:10.3748/wjg.v29.i37.5292
  title: New insights into the pathogenesis of primary biliary cholangitis
    asymptomatic stage
  findings: []

📚

References & Deep Research